StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
6877.HK$0.11-6.19%
Fair $0.11+0.0%

6877.HK

Top Eminent Healthcare Group Limited

Financial Services / Capital MarketsHKSE

$0.11

-0.01 (-6.19%)

Fairly Valued+0.0%Fair Value $0.11Fund rank 23/100 · Data gapFallback financials|
SA 16/F
F-Score: 1/9
Low Profitability

Book/ROE base 3Y

n/d

n/d CAGR · P/B n/d

Book/ROE base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 100% · confianza 20%

Book/ROE escenarios

weak_data · book/share n/d · quality 2.0/100

Data gap 23/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 20/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

16/100

F

Piotroski

1/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); financial Book/ROE targets are disabled until manually verified. ROE is -3.0%, below the 5% threshold
Thesis & Journal · 6877.HKLocal privado en este navegador · Top Eminent Healthcare Group Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$216M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-3.0%

↓

Gross Margin

37.3%

↓

Debt/Equity

N/A

•
52-Week Range$0
$0$0

TradingView lightweight chart

6877.HK price, volumen y niveles de valoración

Último $0.106Periodo -77.2%
Fair value: $0.106

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+39.5%

FCF CAGR

—

FCF margin

-7.5%

FCF / Net income

1.16x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $109.8M · net income $-7.1M · FCF $-8.3M

2022-FY → 2025-FY

Gross margin

37.3%+23.2% pts

Operating margin

-3.4%+19.5% pts

Net margin

-6.5%+70.3% pts

FCF margin

-7.5%+34.0% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$109.8M$109.8M$95.8M$198.9M$40.5M
Net Income$-7.1M$-7.1M$11.3M$9.8M$-31.1M
EBITDA$-3.7M$-3.7M$6.7M$14.7M$-8.2M
EPS——0.010.00-0.02
Gross Margin37.3%37.3%39.2%21.3%14.1%
Operating Margin-3.4%-3.4%6.7%7.2%-22.9%
Net Margin-6.5%-6.5%11.8%4.9%-76.8%
Balance Sheet
Current Ratio42.8042.80———
Cash Flow
Free Cash Flow$-8.3M$-8.3M$-19.9M$1.8M$-16.8M
Returns
ROE-3.0%-3.0%4.6%4.1%-13.5%
Valuation
P/E——17.5014.58—
EV/EBITDA——-0.88-5.43—
P/B0.900.900.820.591.28
Growth & Yield
Revenue Growth14.7%14.7%-51.9%391.7%—
EPS Growth——16.7%131.4%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -76.7%

Total return

-76.7%

Start / end P/E

n/dx → n/dx

EPS bridge

0.01 → n/d

Residual

-76.7%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-76.7%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.